Investigational new drugs for the treatment of chronic renal failure: an overview of the literature.

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-28 DOI:10.1080/13543784.2024.2326624

Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro

{"title":"Investigational new drugs for the treatment of chronic renal failure: an overview of the literature.","authors":"Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro","doi":"10.1080/13543784.2024.2326624","DOIUrl":null,"url":null,"abstract":"Introduction: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications.Areas covered: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website.Expert opinion: Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"319-334"},"PeriodicalIF":4.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2024.2326624","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications.

Areas covered: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website.

Expert opinion: Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future.

查看原文本刊更多论文

治疗慢性肾功能衰竭的试验性新药：文献综述。

导言：慢性肾脏病（CKD）在全世界范围内广泛存在，对社会和健康造成了严重影响。肾病学家的主要目标是通过一系列新药延缓肾病的进展并治疗相关症状：本系统综述旨在分析治疗慢性肾功能衰竭的新研究药物。数据来自现有的科学文献和ClinicalTrials.gov网站：在目前正在研究的药物中，SGLT2 抑制剂似乎是最有希望治疗慢性肾功能衰竭的药物，因为它们能减缓慢性肾功能衰竭的进展并保护心肾功能。自体细胞疗法在未来的慢性肾功能衰竭治疗中扮演着重要角色，它似乎是治疗慢性肾功能衰竭的一个新领域。目前正在对其他治疗策略进行研究，这些策略已被证明可以减缓慢性肾功能衰竭的进展。然而，要确定这些方法是否能在不久的将来为减缓慢性肾功能衰竭的进展带来益处，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.